References
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157: 107843.
- Standards of Medical Care in Diabetes. Summary of revisions. Diabetes Care 2016; 39 (Supplement 1):S4-5.
- Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014; 383(9922):1068-83.
- Cai X, Xia L, Pan Y, He D, Zhu H, Wei T, et al. Differential role of insulin resistance and β-cell function in the development of prediabetes and diabetes in middle-aged and elderly Chinese population. Diabetol Metab Syndr.. 2019;11:24.
- Pala L, Barbaro V, Dicembrini I, Rotella CM. The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord. 2014;19(3):275-83.
- Scirica BM. Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus. Clin Chem. 2017; 63(1):186-195.
- Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180-90.
- Maruo S, Mori K, Motoyama K, Nakamura M, Kawarabayashi R, Kakutani Y, et al. Correlation analysis of monocyte subsets and insulin resistance considering fetuin-A involvement in patients with type 2 diabetes. Clin Transl Med, 2018;7:9.
- Komsa-Penkova RS, Golemanov GM, Radionova ZV, Tonchev PT, Iliev SD, Penkov VV. Fetuin-A - alpha2-heremans-schmid glycoprotein: from structure to a novel marker of chronic diseases part 1. Fetuin-A as a calcium chaperone and inflammatory marker. J Biomed Clin Res. 2017;10(2):90-7.
- Ismail NA, Ragab S, El Dayem SM, Elbaky AA, Salah N, Hamed M, et al. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci. 2012;8(5):826-33.
- Alireza E, Mohsen A, Sahar F, SinaN, Manouchehr N. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Diabetes & Metabolic Syndrome. Clin Res Rev. 2015;9(4):258-65.
- Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS, et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. 2000; 164(1-2):87-98.
- Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012; 18(8):1279-85.
- Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019;11(3):45-63.
- Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol. 2011;75(4):450-455.
- Shivakumar. N, Kumar M, Ashwathanarayana M, Venkatesh M, Sheshadri M, Deshmukh S, et al. Role of retinol-binding protein 4 in obese Asian Indians with metabolic syndrome. J Med Biochem. 2012;31(1):40-6.
- Khadir A, Kavalakatt S, Madhu D, Hammad M, Devarajan S, Tuomilehto J, et al. Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation. Lipids Health Dis. 2018;17(1):291.
- Jin C, Lin L, Han N, Zhao Z, Liu Z, Luo S, et al. Effects of dynamic change in fetuin-A levels from the first to the second trimester on insulin resistance and gestational diabetes mellitus: a nested case-control study. BMJ Open Diab Res Care. 2020; 8(1):e000802.
- Goustin AS, Abou-Samra AB. The "thrifty" gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal. 2011; 23(6): 980-90.
- Bourebaba L, Marycz K. Pathophysiological implication of fetuin-a glycoprotein in the development of metabolic disorders: A concise review. J Clin Med. 2019; 8(12): 2033.
- Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev. 2008; 29(7): 939-60.
- Yin L, Cai WJ, Chang XY, Li J, Su XH, Zhu LY, et al. Association between fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus. Biomed Rep. 2014; 2(6): 839-42.
- Yin L, Cai WJ, Zhu LY, Li J, Su XH, Wang XL, et al. Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. Int J Clin Exp Med. 2015; 8(1): 991-9.
- Sharma B, Sarmah D. WC is better than BMI as a predictor of diabetes and prediabetes in Hindu priests of India. Asian J Med Sci. 2015; 6(1): 91-4.
- Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015; 159(3): 352-9.
- Vörös K, Gráf L, Prohászka Z, Gráf L, Szenthe P, Kaszás E, et al. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest. 2011; 41: 703-9.
- Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the US. Diabetes. 2013; 62(1): 49-55.
- Song A, Xu M, Bi Y, Xu Y, Huang Y, Li M, et al. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. Plos One. 2011; 6(4): e19228.